Response to "Neoadjuvant or Perioperative Chemoimmunotherapy Treatment in Patients With Resectable NSCLC: Still an Open Question" by Dafni et al [0.03%]
对Dafni等关于“可切除NSCLC患者的新辅助或围手术期化疗免疫治疗：仍然存在争议”的回应
Daniele Marinelli,Giuseppe Viscardi,Roberto Ferrara et al.
Daniele Marinelli et al.
Broadening the Scope of Bronchoscopic Sampling in the Era of Minimally Invasive and Molecular Diagnosis of Lung Cancer [0.03%]
微创和分子诊断时代的支气管镜取样范畴扩大化
Tracy L Leong,Daniel P Steinfort
Tracy L Leong
Optimizing First-Line Treatment in BRAF V600-Mut NSCLC-The Jury Is Still Out [0.03%]
BRAF V600突变型晚期非小细胞肺癌一线治疗的优化仍在研究中
Alona Zer,Jair Bar
Alona Zer
Where Do We Go With the Combination of Immune Checkpoint Inhibitors With Anti-Angiogenesis in Advanced NSCLC? [0.03%]
免疫检查点抑制剂与抗血管生成药物联合治疗晚期非小细胞肺癌的前景展望
Fen Wang,Alex A Adjei
Fen Wang
Setting Expectations: Using Real-World Data to Guide Patients on Frontline Osimertinib [0.03%]
确立患者的期望值：真实世界数据引导一线奥希替尼治疗患者的效果评估
Jennifer W Carlisle,Ticiana Leal
Jennifer W Carlisle
Dual Targets, Two Paths: Amivantamab: A Promising Treatment for NSCLC With Exon 14 Skipping Mutations of MET [0.03%]
双重目标，两条道路：艾伏那布塔姆——跳过MET外显子14突变的非小细胞肺癌患者的前景疗法
Daiki Murata,Hidetoshi Hayashi
Daiki Murata
Patricia de Groot,Jeremy Erasmus,Ioannis Vlahos
Patricia de Groot
So Yeon Kim,Katerina Politi,Sarah B Goldberg
So Yeon Kim
Screening-Detected versus Interval Lung Cancer in the Biennial Korean National Lung Cancer Screening Program: Proportion, Characteristics, and Mortality [0.03%]
韩国每两年一次的全国肺癌筛查项目中筛查发现与间期肺癌的比例、特征及死亡率
Hyungjin Kim,Eunseo Jo,Jinseob Kim et al.
Hyungjin Kim et al.
Introduction: Interval lung cancers (ILCs) are key indicators of lung cancer screening (LCS) performance. However, data on the proportion, characteristics, and mortality of ILCs under biennial screening in Asian populatio...
Translational analysis of NSD3 gene amplification in lung squamous cell carcinoma: Clinical and prognostic insights from histopathological analysis of patient samples [0.03%]
染色体易位基因扩增的转化分析：来自病理组织芯片分析的临床和预后见解
Shugo Takahashi,Tetsuro Taki,Nobuyuki Nakamura et al.
Shugo Takahashi et al.
Introduction: Nuclear receptor-binding SET domain 3 (NSD3) has been implicated as a driver of lung squamous cell carcinoma (LUSC) in preclinical studies. However, its clinicopathological characteristics and prognostic sig...